Karyopharm Therapeutics (KPTI) Net Shares Issued and Repurchased (2013 - 2025)

Karyopharm Therapeutics (KPTI) has reported Net Shares Issued and Repurchased for 11 consecutive years, with $271787.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Shares Issued and Repurchased fell 89.83% year-over-year to $271787.0; the trailing twelve-month figure through Dec 2025 stood at $271787.0 (down 89.83% YoY), and the FY2025 full-year result was $271787.0, down 89.83% from the prior year.
• Net Shares Issued and Repurchased slipped to $271787.0 in Q4 2025 per KPTI's latest filing, from $2.7 million in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $722.9 million in Q4 2022 and bottomed at $271787.0 in Q4 2025.
• Historically, Net Shares Issued and Repurchased has averaged $146.6 million across 5 years, with a median of $3.6 million in 2021.
• The sharpest annual moves came in 2022 and 2023: Net Shares Issued and Repurchased jumped 20117.2% in 2022, then plunged 99.51% in 2023.
• Over 5 years, Net Shares Issued and Repurchased stood at $3.6 million in 2021, then surged by 20117.2% to $722.9 million in 2022, then slumped by 99.51% to $3.6 million in 2023, then fell by 25.34% to $2.7 million in 2024, then slumped by 89.83% to $271787.0 in 2025.
• According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $271787.0, $2.7 million, and $3.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.